Ceftriaxone Sodium belongs to the antibiotic class and achieves its selective antibacterial effect by inhibiting a bacterial enzyme or structural component essential for pathogen survival and replication while maintaining a defined safety margin against mammalian cell toxicity. The selectivity index between the antibacterially effective concentration and the mammalian cytotoxic concentration defines the therapeutic window. PDE derivation for Ceftriaxone Sodium draws on the critical repeat-dose toxicity study in rodents or higher species, with the NOAEL serving as the point of departure before application of composite uncertainty factors.
Health-based exposure limits for Ceftriaxone Sodium require formal periodic review as new toxicological evidence, clinical safety data, or regulatory agency assessments become available. Pharmaceutical manufacturers are expected to maintain a defined review cycle—typically every 3–5 years or triggered by significant new findings—and to update OEL, PDE
